Servando Cardona‐Huerta

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina et al. · The Lancet · 2016 · 580 citations · Full text

Mg Versus, Breast Oncology, Oncology +8

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 244 citations · Full text

Is Head and Neck Melanoma Different from Trunk and Extremity Melanomas with Respect to Sentinel Lymph Node Status and Clinical Outcome?

Niloofar Fadaki, Rui Li, Brian M. Parrett et al. · Annals of Surgical Oncology · 2013 · 97 citations

Medicine, Melanoma, Extremity Melanomas +8

A New Gene Expression Signature for Triple-Negative Breast Cancer using Frozen Fresh Tissue before Neoadjuvant chemotherapy

Sandra K. Santuario-Facio, Servando Cardona‐Huerta, Yadira X. Pérez-Páramo et al. · Molecular Medicine · 2017 · 51 citations · Full text

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg et al. · Supportive Care in Cancer · 2016 · 47 citations · Full text